other material
confidence high
sentiment positive
materiality 0.75
Caribou reports vispa-cel 82% ORR, 17.1mo mPFS in 2L LBCL; CB-011 83% CR rate in MM
Caribou Biosciences, Inc.
- Vispa-cel in 27 optimized 2L LBCL patients: 82% ORR, 67% CR, 17.1 months median PFS.
- Vispa-cel safety: no GvHD, no grade 3+ ICANS; one grade 3+ CRS; one related death (IEC-HS).
- FDA aligned on ANTLER-3 phase 3 design for vispa-cel; ~250 CD19-naïve 2L LBCL patients, primary endpoint PFS.
- CB-011 in 12 BCMA-naïve r/r MM patients at RDE: 92% ORR, 83% ≥CR, 91% MRD negativity, 50% in ≥CR at 15 months.
- CB-011 case study: patient after 8 prior lines (incl. autologous CAR-T) achieved CR; dose expansion data expected H2 2026.